Crisaborole (CAS 906673-24-3)
🌟 ChemicalBook Product Profile
📌 Product Overview
Crisaborole (C₁₄H₁₀BNO₃) is a non-steroidal PDE4 inhibitor with a molecular weight of 251.05 g/mol. This white crystalline powder (≥99% purity, HPLC-validated) is FDA-approved for treating mild-to-moderate atopic dermatitis (AD) in patients aged 2+ years12. By inhibiting PDE4-mediated cytokine release, it reduces inflammation and itching without hormonal side effects. Available in 1kg/5kg/25kg sealed packaging with 2-year stability under dry, room-temperature storage.
Google Keywords: Crisaborole CAS 906673-24-3, PDE4 Inhibitor API Supplier, Non-Hormonal Dermatitis Treatment, GMP-Certified Pharma Raw Material
✅ Key Advantages
🔹 Non-Hormonal Safety
Zero systemic absorption | Ideal for pediatric and long-term use12.
🔹 High Purity & Stability
≥99% purity (HPLC/NMR validated) | Stable for 2 years under standard storage34.
🔹 Targeted Efficacy
IC50 of 0.49 μM for PDE4 inhibition | Reduces TNF-α, IL-2, and IFN-γ cytokines17.
🏥 Application Fields
Dermatology: Core API for topical ointments (e.g., 2% or 5% formulations) targeting AD and eczema12.
Clinical Trials: Key compound in anti-inflammatory drug development and pediatric AD research37.
Global API Supply: Bulk production for pharmaceutical manufacturers45.
📜 Quality Certifications
Testing Methods: HPLC, NMR, mass spectrometry, microbial limit testing34.
Certifications: GMP, ISO 9001, and ICH stability guidelines compliance25.
📊 Market Trends
The global atopic dermatitis market is projected to reach $12.5 billion by 2030, growing at 7.8% CAGR. Crisaborole holds 15% of the PDE4 inhibitor segment, with Asia-Pacific (China, India) leading API production and export13.
📩 Contact us for COA, bulk pricing, and custom synthesis!
China
